Stay updated on Regeneron Press Releases

Sign up to get notified when there's something new on the Regeneron Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Regeneron Press Releases page

  1. Check
    3 days ago
    Change Detected
    Summary
    Added a new press release item titled 'Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO' dated June 4, 2026 7:00 AM EDT. Removed the previously listed press release 'Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.' dated April 23, 2026 3:46 PM EDT.
    Difference
    2%
    Check dated 2026-06-05T08:26:24.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    Two new press releases were added to the press releases page: Regeneron’s Ebola antibody was recommended by the World Health Organization for investigational use in response to a Bundibugyo ebolavirus outbreak, and Otarmeni (lunsotogene parvec) received EMA filing acceptance for genetic hearing loss. At the same time, two older items were removed from the listing: the FDA approval of Otarmeni-cwha for genetic hearing loss and the Dupixent approval for young children with CSU.
    Difference
    6%
    Check dated 2026-05-29T06:26:37.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The press releases list was updated to include several May 2026 announcements, and earlier April items were deleted, reflecting the latest company news on the investor site.
    Difference
    6%
    Check dated 2026-05-22T04:38:44.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    A new press release entry was added announcing Regeneron's Dow Jones Best-in-Class recognition for seven consecutive years. An older press release about a TriNetX collaboration was removed from the listing.
    Difference
    2%
    Check dated 2026-05-14T22:53:25.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    Added a new press release: Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial, May 5, 2026 7:00 AM EDT. Removed the EYLEA HD® (aflibercept) FDA approval release, April 2, 2026 12:00 PM EDT.
    Difference
    2%
    Check dated 2026-05-07T20:05:48.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    Three new press releases were added to the listing (Q1 2026 financial results; U.S. government drug-cost agreement with a free gene therapy; FDA approval of Otarmeni), and three older entries were removed from the page.
    Difference
    6%
    Check dated 2026-04-30T15:54:00.000Z thumbnail image

Stay in the know with updates to Regeneron Press Releases

Enter your email address, and we'll notify you when there's something new on the Regeneron Press Releases page.